This study offers a valuable methodological advance by introducing a gene panel selection approach that captures combinatorial specificity to define cell identity. The findings address key limitations ...
NLS Pharmaceutics Ltd. ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback